Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 3.9% - What's Next?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) were down 3.9% during trading on Wednesday . The stock traded as low as $4.98 and last traded at $5.02. Approximately 8,310,275 shares were traded during trading, a decline of 46% from the average daily volume of 15,485,904 shares. The stock had previously closed at $5.22.

Analysts Set New Price Targets

Several brokerages recently issued reports on RXRX. Needham & Company LLC cut their target price on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Leerink Partners dropped their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday, February 28th. Morgan Stanley reduced their target price on Recursion Pharmaceuticals from $8.00 to $5.00 and set an "equal weight" rating for the company in a research note on Monday, June 16th. Finally, Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $7.00.

Recursion Pharmaceuticals Stock Up 4.7%

The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.11 and a current ratio of 4.11. The stock's 50 day simple moving average is $4.89 and its 200 day simple moving average is $6.19. The firm has a market cap of $2.20 billion, a P/E ratio of -3.05 and a beta of 0.84.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The business had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. During the same quarter in the prior year, the business earned ($0.39) earnings per share. The firm's quarterly revenue was up 7.2% compared to the same quarter last year. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Institutional Trading of Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers lifted its holdings in shares of Recursion Pharmaceuticals by 7.5% in the first quarter. Rhumbline Advisers now owns 359,175 shares of the company's stock valued at $1,900,000 after purchasing an additional 25,143 shares in the last quarter. Focus Partners Wealth purchased a new stake in Recursion Pharmaceuticals in the 1st quarter valued at $77,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Recursion Pharmaceuticals by 183.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company's stock valued at $33,901,000 after buying an additional 4,149,346 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Recursion Pharmaceuticals by 7.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company's stock valued at $953,000 after acquiring an additional 12,372 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new position in Recursion Pharmaceuticals during the 1st quarter worth $890,000. 89.06% of the stock is owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.